CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or...
Phase 1
San Antonio, Texas, United States and 3 other locations
is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...
Phase 1
San Antonio, Texas, United States and 16 other locations
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of ....
Phase 1
San Antonio, Texas, United States and 6 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....
Phase 1, Phase 2
San Antonio, Texas, United States and 15 other locations
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer...
Phase 1
San Antonio, Texas, United States of America and 2 other locations
dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...
Phase 1
San Antonio, Texas, United States of America and 32 other locations
tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors...
Phase 1, Phase 2
San Antonio, Texas, United States and 52 other locations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutation...
Phase 1
San Antonio, Texas, United States and 8 other locations
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced ...
Phase 1, Phase 2
San Antonio, Texas, United States and 13 other locations
to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combinatio...
Phase 1
San Antonio, Texas, United States of America and 57 other locations
Clinical trials
Research sites
Resources
Legal